Eplontersen continued to show improvement in ATTRv-PN through 85 weeks

Topline Phase 3 NEURO-TTRansform results show eplontersen continued to halt neuropathy disease progression and improve quality of life through 85 weeksData further strengthen eplontersen's...

Related Keywords

Eugene Schneider ,Drug Administration ,Exchange Commission ,Ionis Pharmaceuticals Inc ,Twitter ,Astrazeneca ,Ionis Pharmaceuticals ,Prnewswire Ionis Pharmaceuticals Nasdaq ,Topline Phase ,Neuropathy Impairment Score ,Norfolk Quality ,Life Questionnaire Diabetic Neuropathy ,New Drug Application ,Orphan Drug Designation ,Conjugated Antisense ,